ArticleHepatology international2019
Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma.
Article in Hepatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Computational modeling and expression of recombinant interleukin 15-R-Tf-D-LP4 peptide fusion protein: a potent candidate for hepatocellular carcinoma.Biotechnology letters · 2026Article
- Triple-armed oncolytic HSV enhances antitumor immunity by remodeling the tumor microenvironment in subcutaneous murine CRC.iScience · 2026Article
- The acidic tumor microenvironment in hepatocellular carcinoma: a barrier to adoptive cellular immunotherapy.Frontiers in immunology · 2026Review
- Glypican-3-Specific CAR NK Cells Co-Secreting IL-15 and IFN-α Have Increased Anti-Tumor Function Versus Hepatocellular Carcinoma In Vitro.International journal of molecular sciences · 2025Article
- Ultrasoft hydrogel immune millirobot with multimodal locomotion.Science advances · 2025Article
- Surface-Engineered Natural Killer Cell-Derived Small Extracellular Vesicles Induce Potent Anti-Tumour Effects in Lung Cancer Cells.Journal of extracellular biology · 2025Article
- Elephant in the room: natural killer cells don't forget HIV either.Current opinion in HIV and AIDS · 2025Review
- Article
- Natural killer cell memory: challenges and opportunities for cancer immunotherapy.Cancer biology & therapy · 2024Review
- Sorafenib plus memory-like natural killer cell immunochemotherapy boosts treatment response in liver cancer.BMC cancer · 2024Article
- Cell-cell communication: new insights and clinical implications.Signal transduction and targeted therapy · 2024Review
- Proliferation capability of natural killer cells upon cytokines stimulation correlated negatively with serum lactate dehydrogenase level in coronary artery disease patients.Frontiers in immunology · 2024Article
- Sorafenib plus memory like natural killer cell combination therapy in hepatocellular carcinoma.American journal of cancer research · 2024Article
- PM21-particle stimulation augmented with cytokines enhances NK cell expansion and confers memory-like characteristics with enhanced survival.Frontiers in immunology · 2024Article
- Harnessing the power of memory-like NK cells to fight cancer.Clinical and experimental immunology · 2023Article
- Article
- The application of autologous cancer immunotherapies in the age of memory-NK cells.Frontiers in immunology · 2023Review
- Attenuated Cytokine-Induced Memory-Like Natural Killer Cell Responses toInfection and drug resistance · 2023Article
- Protein phosphatases regulate the liver microenvironment in the development of hepatocellular carcinoma.Experimental & molecular medicine · 2022Review
- Costimulatory CD226 Signaling Regulates Proliferation of Memory-like NK Cells in Healthy Individuals with LatentInternational journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is common, but remains difficult to treat. Natural killer (NK) cells are cells of the innate immune system that have potent anti-cancer activity. Recent work has shown that stimulation with IL-12/15/18 leads to the generation of NK cells with enhanced functional and putative "memory" properties. We have investigated the activity of these NK cells against HCC cell lines in vitro and in a mouse model.
methodsNK cells from healthy donors or individuals with HCC were activated with IL-12/15/18 in vitro and tested for cytotoxic activity against a panel of human HCC cell lines. IL-12/15/18 primed murine NK cells were then infused into a murine model of spontaneously arising HCC to test for anti-tumor activity.
resultsNK cells from patients and healthy controls had similar expression levels of activating and inhibitory NK cell receptors. However, proliferation of NK cells from HCC patients was weaker than healthy controls in response to IL-12/15/18 and IL-2 (p < 0.001 at day 9). In vitro, NK cells from both groups of individuals killed HCC targets to similar levels and this was unrelated to NKG2D expression. In a spontaneous model of HCC, IL-12/15/18 activated NK cells trafficked to the liver and resulted in lower levels of spontaneous HCC formation (p < 0.01).
conclusionCytokine-primed NK cells from patients with HCC have similar levels of activity against HCC cell lines as those from healthy controls. This type of activated NK cell has immunotherapeutic potential against hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.